CBIS another deal.....AMVA price target hiked.....HJOE for channeling

 

Focus:

 

Sharp buying on dip below flatline...

AMBA

11:51am EDT

88.93

+1.73

+1.98%

87.63

90.77

1,383,828

1,587,700

2.78B

Chart, News, Stats, Options, Board

AMBA	Ambarella (AMBA) Stock Price Target Hiked at KeyBanc at TheStreet Wed 10:04am

 

 

 

 

 

 

ENDO closed down...Taking stab at flatline however....May have topped out short term, but the recent trending took out 52wk highs on heavy vol....

ENDO

11:33am EDT

0.0232

-0.0028

-10.77%

0.0231

0.027

167,744

206,941

-

 

 

 

 

CERE

11:50am EDT

3.85

+2.17

+129.06%

1.77

4.04

8,355,661

220,269

23.28M

 

 

 

Recall HJOE two runups to .005 from  .002 in last month....Pay closer attention now that it's back near lower end of channel..

HJOE

11:36am EDT

0.0025

-0.0011

-30.56%

0.0023

0.0036

111,858,737

117,648,000

1.0051M

 

 

 

 

Coverage stock CBIS keeps getting bought into under .03 we've been witnessing all month.....another op after earlier gap on the new deal...HIV is a market they are doing major research on...

 

CBIS	Lexaria Looks to Validate Breakthrough Technology at Accesswire Wed 10:00am

 

CBIS	Cannabis Science Brings CS-TATI-1 to the FDA with Historic Collaborative Drug Development Deal With IGXBio and Its GenePro®, a DNA-Based Immunotherapeutic that Recently Received FDA Approval to Enter into Human Trials at PR Newswire Wed 8:05am

 

 

COLORADO SPRINGS, Colo., May 27, 2015 /PRNewswire/ -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabis-based medicine and related consulting, has announced a Historic Collaborative Drug Development deal with IGXBio and its GenePro®, a DNA-based immunotherapeutic that recently received FDA IND approval to enter into human trials. The companies intend to develop a joint protocol to demonstrate potential synergistic effects of their respective drug candidates in HIV, as well as potential new drug candidates.

Mr. James Laufenberg, President and CEO of IGXBio, stated, "I am very excited about this collaboration with Cannabis Science, a company based on our own values of serving the unmet needs of HIV positive patients. The GenePro® technology has been published in over 150 scientific journals. GenePro® is intended to promote an anti-HIV immune response to facilitate virus control in HIV-infected subjects. The pre-clinical development to date has been largely funded by $21 million in NIH grants. Our collaboration with Cannabis Science is designed to create new products for clinical development and commercialization in addition to utilizing GenePro® in a Phase I/IIa clinical trial."

"Inflammation is the body's immune response to HIV that occurs at even low levels of HIV replication. It is a major contributor to the co-morbidities that promote morbidity and mortality in people with HIV, despite successful antiretroviral therapy such as heart disease, bone disease and cancers. If inflammation can be lowered or eliminated along with HIV viral replication it will successfully improve the health and extend the lives of HIV-positive people. By partnering CS-TATI-1 and GenePro® we believe this is possible," stated Dr. Roscoe M. Moore, Jr., DVM, MPH, Ph.D., DSc., Former Asst. US Surgeon General and Cannabis Science Special Senior Advisor and Member of the Company's Scientific Advisory Board.

"The collaboration between IGX Bio and CBIS is intended to help provide new insights into the role of inflammation and therapeutic vaccination of HIV as a critical step for optimizing effective treatments for AIDS patients in various resource settings.  These studies will provide a scientific evaluation of GenePro® and CS-TATI-1 to demonstrate the enhanced potential of therapeutic vaccination and the anti-inflammatory effects of cannabinoids to deter disease progression in AIDS patients unable to achieve control HIV replication," stated Mr. Raymond C. Dabney, Cannabis Science, Inc., President & CEO, Co-Founder.

About IGXBio